To investigate the roles of SUMO-specific protease 1 (SENP1) in triple-negative breast cancer (TNBC), we detected the expression level of SENP1 in the clinical samples of TNBC and non-TNBC patients by using immunohistochemical staining, qRT-PCR, and western blotting. We found that SENP1 was highly expressed in the TNBC tissues compared with the normal breast tissues, as well as non-TNBC tissues. Next, we constructed the si-SENP1-transfected TNBC cell lines for further biological function investigation. Then a xenograft model of nude mice was constructed to confirm the roles of SENP1 in TNBC formation and metastasis. According to our results, deficiency of SENP1 significantly represses the proliferation, invasion, migration, and colony formation of TNBC cells through blocking the cell cycle and regulating the expression of cyclin-dependent kinases (CDKs) p21 and p27, as well as MMP9. Furthermore, in vivo experiments revealed that depletion of SENP1 remarkably inhibits the tumor volume, lung metastatis and the expression of p21, p27, MMP9, and Ki67. Taken together, this study elucidated that SENP1 is essential for TNBC cell proliferation and migration in vitro, as well as tumor formation and metastasis in vivo, indicating that SENP1 is a potential therapeutic target for TNBC treat-
Introduction
Despite the rapid development of diagnosis and treatment in recent decades, breast cancer is still the second leading cause of cancer death in women (1) . Based on clinical, pathological, and genetic findings, it is comprised of distinct subtypes (2) , one of which is triple-negative breast cancer (TNBC). TNBCs are distinguished by lack of estrogen receptor (ER), progesterone receptor (PR), and amplification of the human epidermal growth factor receptor 2 (HER2) (3), accounts for >15% of all breast cancers (4) and are more prevalent in young, African-American, and Latino women. Compared with other breast cancer subtypes, TNBC patients have more aggressive clinical course, higher rate of distant recurrence and poorer prognosis (3, 5, 6) . Thus, it is essential to develop novel diagnostic and therapeutic methods for TNBC patients.
Sentrin/SUMO-specific protease 1 (SENP1), a member of SUMO-specific protease (SENP) family, is widely distributed in the nuclei (7, 8) . SENP1 can deconjugate large numbers of sumoylated proteins. Previously, many studies reported that SENP1 was overexpressed in human prostate cancer (CaP) cells (9) , as well as lung cancer tissues (10) and most of colon cancer tissues (11) . The expression of SENP1 was reported to have strong prognostic impact on a molecularly defined subset of CaPs (12) . Another study revealed that SENP1 might be a prognostic marker and a therapeutic target for metastasis in CaP patients, for its roles in regulating MMP2 and MMP9 through the HIF-1α signaling pathway (13) . Additionally, SENP1 3'-untranslated region was demonstrated as a regulative target of miR-145, which plays an important role in tumorigenesis of CaP (14) . It was reported that the miR-138/SENP1 cascade was relative to radiosensitization in lung cancer cells (15) . Silencing of SENP1 expression results in upregulation of cyclin-dependent kinase (CDK) inhibitors such as p16, p19, p21 and p27, further inhibits cell growth and colony formation in colon cancer cell line, suggesting that SENP1 is essential for cell growth in the colon cancer cell line (11) . Moreover, clinical data showed that SENP1 was positively associated with lymph node metastasis and TNM stage of pancreatic cancer (16) . In Burkitt's lymphoma, downregulation of SENP1 expression can reduce the stability of HIF-1α protein and induce the apoptosis of Daudi cells (17) . Since the important roles of SENP1 in various cancers, the expression level of SENP1 and whether it is involved in TNBC still requires investigation.
In this study, we firstly investigated the expression of SENP1 in the clinical samples of TNBC and non-TNBC patients by using qRT-PCR, western blotting, and immunohistochemical staining. Our results indicated that SENP1 was highly expressed in TNBC tissues compared with normal were purchased from ATCC (Rockville, MD, USA) and all cell lines except HMLE were routinely maintained in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) and 50 U/ml penicillin -50 µg/ml streptomycin antibiotics (Gibco). HMLE cells were cultured in DMEM/F12 containing growth factor, insulin, hydrocortisone, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cell lines were cultured in a 37˚C incubator with humidified atmosphere of 5% CO 2 .
Cell transfection. The retrovirus containing SENP1 siRNA or non-specific siRNA as described previously (8) no. T9300). The protein extracts were equally loaded onto 10% SDS polyacrylamide gels, electrophoresed and transferred to PvDF membranes. The membranes were blocked in 5% fat-free milk in TBST buffer for 2 h at room temperature. The rabbit anti-human polyclonal antibody was used in conjunction with 0.4 µg/ml of anti-species-conjugated horseradish peroxidase. Rabbit anti-human SENP1 polyclonal antibody (cat. no. ab58417), rabbit anti-human p21 polyclonal antibody (cat. no. ab7960), rabbit anti-human p27 polyclonal antibody (cat. no. ab7961), rabbit anti-human MMP9 polyclonal antibody (cat. no. ab38898) and rabbit anti-human β-actin polyclonal antibody (cat. no. ab8227) were purchased from Abcam. The bands were detected by chemiluminescent substrate kit (Millipore Corp.). The intensities of the bands were quantified using the NIH ImageJ software package.
Cell growth assay. Cells were seeded into 6-well plates at a density of 1x10 5 cells/well and cultured in the growth medium. Cell growth was measured by MTT assay and recorded by a Benchmark Microplate Reader (Bio-Rad Laboratories, Inc.) at 0, 2, 4 and 6 days.
Soft agar colony formation assay. Agarose (0.7%) was mixed with cells and placed above the 1.2% agarose underlay. After 2 weeks, colonies were dyed with crystal violet (0.01% solution). Then washed with PBS, the colonies were imaged using a custom, automated plate imager with a digital camera (Olympus SP-350; Olympus Corp.).
Cell cycle assay. Cells were collected and fixed using 75% ice-cold ethanol at -20˚C overnight, then cells were treated with Tris-HCl buffer (pH 7.4) contained with 100 µg/ml RNase A and dyed with propidium iodide (PI; 25 µg/ml). Then, cell cycle distribution was monitored via flow cytometry. The data were collected and analyzed using ModFit software.
Transwell assay. Cells in logarithmic growth phase were treated with trypsin, washed with PBS and then resuspended in serum-free medium. A total of 4x10 6 cells were added to the upper compartment of the invasion chamber, and 500 µl of culture medium were added to the lower compartment of the invasion chamber. Each insert was precoated with 45 µg Matrigel (BD Biosciences, San Jose, CA, USA). The Matrigel invasion chambers were incubated at 37˚C for 48 h in 5% CO 2 . The non-invading cells were removed from the upper face of the membrane and the invaded cells on the lower surface were stained with 0.05% crystal violet for 30 min. After washed with PBS, the invaded cells were subjected to microscopic inspection (DFC500; Leica Microsystems GmbH, Wetzlar, Germany) according to the manufacturer's instructions. Finally, the values for invasion were obtained by counting three fields per membrane. Experiments were independently repeated in triplicate.
Wound healing assay. Cells were seeded into the bottom of 6-well plates marked a horizontal line on the back for targeting the same field of vision. A line wound was made by scraping a 100-µl tip across the confluent cell layer. Cells were washed three times to remove detached cells and debris. Cells were incubated with serum-free medium in a humidified atmosphere containing 5% CO 2 at 37˚C. After cultured for 24 h, wound closure was performed under a light microscope (DFC500; Leica Microsystems GmbH) and measured using Axiovision version 4.7 software (Carl Zeiss Meditec, Dublin, CA, USA). Experiments were independently repeated in triplicate.
Xenograft tumor generation.
A 50-µl suspension containing 5x10 6 tumor cells (si-SENP1 or si-NS cells) was injected subcutaneously into one side of hind flanks of 6-week-old female BALB/c nude mice. The mice were divided into two groups: si-SENP1 (n=8) and si-NS (n=8) group. After 7 days, when tumors had reached a measurable size, tumor size was determined with a caliper and calculated weekly on weeks 1-8. The experiment was repeated three times. After 10 weeks, the mice were sacrificed, and the number of nodules per lung was recorded.
Statistical analysis. The data are expressed as means ± SD and analyzed using GraphPad Prism 5.0 software (GraphPad Software Inc.). Data comparison between the two groups was carried out using the two-tailed Student's t-test. For clinical data, p-value was analyzed by Chi-square test using SPSS 17.0. P<0.05 was considered statistically significant.
Results

SENP1 was highly expressed in TNBC.
Clinical data from TNBC and non-TNBC patients were collected and compared. Statistical analysis of clinical data indicated that the TNBC was significantly correlated with decreased age (P<0.05), increased tumor differentiation grade (P<0.001), and ductal histological type (P<0.001) ( Table I) . To investigate the expression levels of SENP1 in TNBC patients, the tumor tissues and adjacent normal breast tissues were collected from TNBC and non-TNBC patients. Through immunohistochemical staining, qRT-PCR and western blotting, we found that SENP1 was highly expressed in breast cancer tissues compared with the adjacent normal tissues. Additionally, a markedly higher level of SENP1 was observed in TNBC tissues, compared to non-TNBC tissue (Fig. 1A-C ). We then evaluated the level of SENP1 mRNA and protein expression in normal mammary gland cell lines (HMLE and MCF10A), breast cancer cell lines (MCF7, T47D, and ZR-75-1), as well as TNBC cell lines (MDA-MB-231, MDA-MB-453, and MDA-MB-468). Consistent with the tumor tissue results, both SENP1 mRNA and protein were expressed significantly higher in MDA-MB-231 and MDA-MB-453 than other cell lines ( Fig. 1D and E) . These results suggested the potential carcinogenic roles of SENP1 in TNBC.
Depletion of SENP1 inhibited the proliferation and colony formation of TNBC cells.
Due to the high level of SENP1 in TNBC tumor tissues, we subsequently investigated the function of SENP1 in TNBC cell proliferation. Two TNBC cell lines, MDA-MB-231 and MDA-MB-453, were transfected with si-SENP1 and non-specific RNA, as si-NS, respectively. The transfection efficiency was evaluated via qRT-PCR and western blotting ( Fig. 2A and B) . The mRNA levels of SENP1 in si-SENP1-infected cells were <40% compared with si-NS-infected cells. Through MTT assay, we found that knockdown of SENP1 significantly inhibits the proliferation of TNBC cells ( Fig. 2C and E Fig. 2D and F) . These results indicated that silencing of SENP1 could inhibit proliferation and colony formation of TNBC cells in vitro.
Depletion of SENP1 inhibits the invasion, migration, and arrests TNBC cells in G1 phase of the cell cycle.
The effects of SENP1 silencing on cell invasion and migration ability in TNBC cells were detected using Transwell and wound healing assay. As shown in Fig. 3A , silencing of SENP1 significantly reduced the invasion capacity of TNBC cells. Moreover, the results of wound healing assay showed suppressed migration capacity of si-SENP1 TNBC cells (Fig. 3B) . Together, these results revealed the impaired invasion and migration ability of TNBC cells induced by SENP1 deficiency. Additionally, to explore the mechanism of SENP1-mediated functions in cell cycle control, we monitored cell cycle synchronization of TNBC cells using FACS analysis. As shown in Fig. 3C SENP1 is required for the expression of p21, p27, and MMP9 in TNBC cells. Since that SENP-1 promotes metastasis through upregulating MMP9 in prostate and pancreatic cancer (10, 16) , as well as that p21 and p27 were important G1 CDK inhibitors in breast cancer cell proliferation (18) , the previous reports led us to investigate the effect of SENP1 in regulating the expression of p21, p27, and MMP9 in TNBC cells. As shown in Fig. 3D and E, the mRNA and protein levels of p21 and p27 were significantly increased by SENP1 knockdown. However, the expression of MMP9 was decreased in the SENP1-depleting cells. These results indicated that SENP1 regulates cell proliferation of TNBC through controlling the expression of p21 and p27, and modulates cell invasion by altering the level of MMP9.
Silencing of SENP1 inhibits tumor growth and lung metastases in vivo.
To explore the effect of SENP1 on TNBC tumor growth in vivo, cells transfected with si-NS and si-SENP1 were subcutaneously injected into nude mice, respectively. The volume of tumor was evaluated weekly from 1 to 8 weeks after transplantation. As shown in Fig. 4A and B, the tumor sizes in si-SENP1 group were significantly smaller than that in the control group. Pulmonary metastasis detection revealed that si-SENP1 cells had less lung metastases than si-NS control cells (Fig. 4C) . Further, we performed IHC assay by using Ki67 antibody. We found that the expression level of Ki67 in SENP1-depleting tumor cells is lower than that in the control cells, which suggested that depletion of SENP1 would inhibit TNBC cell proliferation in vivo (Fig. 4D) . Furthermore, as shown in Fig. 4E , the protein levels of p21, p27, and MMP9 were increased in tumor tissues from si-SENP1 TNBC cells in comparison with those from si-NS TNBC cells. These results elucidated the in vivo function of SENP1 in regulating TNBC cell proliferation and tumor formation.
Discussion
The SENPs play a pivotal role in maintaining ordered cellular physiology by modulating the balance between sumoylated and unsumoylated proteins. In mammalian cells, there are six identified SENP isoforms, namely SENP1, SENP2, SENP3, SENP5, SENP6, and SENP7, respectively. Emerging studies have demonstrated that various SENP isoforms were involved in the development of diverse diseases, such as pancreatic (16), colon (11) , prostate (19, 20) , bladder (21) and thyroid (22) cancer, as well as heart diseases (23) . SENP1 is the first identified and most characterized SENP among the SENP family. Data from previous studies showed abnormal expression of SENP1 in several types of carcinomas. Wang et al reported that the expression of SENP1 is directly associated with CaP aggressiveness and recurrence. The absence of SENP1 restricted the tumor growth and metastasis in CaP cells (10) . Moreover, SENP1 was increased in pancreatic cancer cells and knockdown of SENP1 inhibited the proliferation, migration, and invasion of pancreatic cancer cells (16) . In this study, we found that SENP1 levels were markedly elevated in TNBC tissues. Through further in vitro and in vivo assays, we elucidated that knockdown of SENP1 modulated the proliferation, mobility, and cell cycle of TNBC cells.
Cell cycle was regulated by the activation of CDKs, which antagonized by the inhibitors, such as p21 and p27 (24, 25) . The expression of p21 and p27 were reported to serve as the molecular basis for cell proliferation blockage in breast cancer cells (18, 26, 27) . For example, the signal transducer and activator of transcription 6 (STAT6) downregulates breast cancer cell proliferation by increasing the expression of p21 and p27 (18) . To further verify the ability of SENP1 to mediate proliferation of TNBC cells, we investigated the expression levels of p21 and p27 in si-SENP1 TNBC cells. We found that silencing of SENP1 increased the expression of p21 and p27 in the two TNBC cell lines, MDA-MB-231 and MDA-MB-453, indicating that SENP1 regulates the proliferation of TNBC cells through repressing the expression of CDK inhibitors, p21, and p27. However, the mechanism of SENP1 in regulating the expression of p21 and p27 needs to be further investigated.
MMPs, the family of Zn-dependent endopeptidases, are associated with the invasive properties of metastatic cancer cells (28, 29) . It has been reported that MMP9 is overexpressed in breast cancer cells and is correlated with the invasion and metastasis of breast cancer (30, 31) . Given that SENP1 affected the cancer invasion and metastasis, we further investigated whether the expression of MMP9 could be controlled by SENP1. Our data showed that knockdown of SENP1 resulted in MMP9 reduction both in mRNA and protein level. In addition, it has been demonstrated that SENP1 regulates the expression of MMP9 through HIF-1α signaling in CaP cells (20) . Thus, it could be an interesting point to confirm whether SENP1 regulates TNBC cell proliferation via HIF-1α pathway.
In conclusion, we demonstrated that SENP1 was upregulated in TNBC tumor tissues when compared to adjacent normal and non-TNBC tumor tissues, respectively. Depletion of SENP1 attenuated TNBC cell proliferation, invasion, migration, and colony formation ability, and arrested TNBC cells in G1/G0 cell cycle progression in vitro, as well as the tumor size, tumor cell proliferation, and lung metastases in vivo. Furthermore, knockdown of SENP1 increased the expression of CKD inhibitors, p21 and p27, and decreased the expression of MMP9. Taken together, the current study elucidated a critical role of SENP1 in TNBC progression, which highlighted that SENP1 might be a potential therapeutic target for TNBC.
